What is Titan Pharmaceuticals, Inc. (TTNP)?

Titan Pharmaceuticals, Inc. (TTNP) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of TTNP?

The current price of TTNP is $2.34. Prices are updated in real time on Stocks360.

What is TTNP's price-to-earnings (PE) ratio?

TTNP's trailing twelve-month PE ratio is -0.01, based on current price and earnings per share data available on Stocks360.

What is TTNP's market capitalization?

TTNP's market capitalization is $3,112,748.00, placing it in the small-cap tier.

Titan Pharmaceuticals, Inc. (TTNP)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$2.34

Market Cap

$3.11M

PE (TTM)

-0.01

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.38

Day Range

$2.30 – $2.69

52-wk Range

$2.33 – $15.15

Avg Volume

N/A

Volume

131.90K

Titan Pharmaceuticals, Inc. (TTNP) is a publicly traded company in the Healthcare sector. Latest price: $2.34. Market cap $3.11M. Trailing PE -0.01. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 31, 2023

EPS $-3.61 vs est. $-4.40

Beat by $0.79

Proprietary Signals

Signal snapshot temporarily unavailable.

About Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc. is a pharmaceutical company dedicated to creating treatments for chronic conditions, with its product development centered around ProNeura, a unique platform designed for extended drug release. Currently, the company markets the Probuphine implant in Canada and the European Union. This implant provides maintenance treatment for clinically stable individuals struggling with opioid use disorder. Beyond Probuphine, Titan Pharmaceuticals is advancing several pipeline candidates. Among these is the kappa opioid agonist peptide program (TP-2021), which utilizes the ProNeura technology to address chronic pruritus. Another key development is a nalmefene implant program, aimed at preventing opioid relapse in patients after detoxification from opioid use disorder. Furthermore, the company is exploring other applications for its ProNeura platform, including a single implant for HIV prevention and a contraceptive option for women and adolescent girls. Established in 1992, Titan Pharmaceuticals operates from its base in South San Francisco, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.01×
P/S (TTM)	0.00×
P/B	0.00×
PEG	0.00×
P/FCF (TTM)	-1.22×
EV / EBITDA	-1.46×
EV / Sales	0.00×
Earnings Yield	-82136.75%
Free Cash Flow Yield	-81.82%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.78M
Net Income (TTM)	-$2.56B
Free Cash Flow (TTM)	-$2.55M
Net Debt	-$328.00K
Working Capital	$1.06M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-91.12%
Return on Invested Capital	-121.03%